Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | PDE1A | P54750 | 1/20 | 0.47 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19375074 | 0.81 | PDE3B (0.53) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL19358218 | 0.81 | NOTUM (0.53) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL19375087 | 0.81 | CYP19A1 (0.47) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3490259 | 0.80 | LMNA (0.63) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3320465 | 0.78 | ENPP2 (0.53) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL7425462 | 0.76 | PDE2A (0.46) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL993223 | 0.76 | LMNA (0.58) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1449607 | 0.76 | LMNA (0.58) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL14259451 | 0.76 | LMNA (0.58) | LMNAMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6259515 | 0.76 | LMNA (0.58) | LMNAMAPTCYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2953457-A2 | ERK INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| EP-0691967-B1 | NITROGEN-CONTAINING FUSED-HETEROCYCLE COMPOUNDS | EISAI CO LTD (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5707998-A | CYCLIC-GMP PHOSPHODIESTERASE INHIBITORS, TREATING CARDIOVASCULAR DISORDERS AND ASTHMA | EISAI CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| WO-1994022855-A1 | NITROGEN-CONTAINING FUSED-HETEROCYCLE COMPOUNDS | EISAI CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | LMNA 4037/4885MAPT 1618/4885CYP19A1 2309/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | LMNA 3554/4885MAPT 1734/4885CYP19A1 3450/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | LMNA 4037/4885MAPT 1618/4885CYP19A1 2309/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | LMNA 4037/4885MAPT 1618/4885CYP19A1 2309/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | LMNA 4037/4885MAPT 1618/4885CYP19A1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.